Instrument Inactif

Communiqués Amniotics AB

Actions

AMNI

SE0015961016

Recherche biotechnologique et médicale

Communiqués

20/08/24	Amniotics H1 2024 - Merger with Magle	AQ
06/08/24	Amniotics receives conditional approval to delist from Nasdaq First North Growth Market	AQ
06/08/24	Amniotics applies for delisting from Nasdaq First North Growth Market conditional upon completion of the merger with Magle Group	AQ
30/05/24	Statement from the Board of Directors of Amniotics regarding the merger with Magle Group	AQ
21/05/24	Amniotics secures continued short-term capital needs by extending loan agreement and continued services under service agreement	AQ
22/03/24	Statement from the Board of Directors of Amniotics regarding the public offer from Magle Chemoswed	AQ
21/03/24	Amniotics secures short-term capital needs by extending loan agreement and entering into a service agreement	AQ
11/03/24	Amniotics announces the outcome of the exercise of warrants series TO 3	AQ
26/02/24	The exercise period for warrants series TO 3 in Amniotics begins today	AQ
26/02/24	Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding	AQ
22/02/24	Amniotics AB (publ) Report for the fourth quarter 2023.	AQ
21/12/23	Information about the Annual General Meeting and appointed Nomination Committee of Amniotics	AQ
14/12/23	Amniotics receives orphan designation for PulmoStem® from the European Commission for the Treatment of Primary Graft Dysfunction following Lung Transplantation	AQ
28/11/23	Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study	AQ
27/11/23	Amniotics AB (publ) Report for the third Quarter 2023	AQ
23/11/23	Renewed GMP certification	AQ
20/11/23	Amniotics receives positive opinion on orphan designation for PulmoStem® from the European Medicines Agency for the Treatment of Primary Graft Dysfunction following Lung Transplantation	AQ
17/11/23	Last day of trading in paid subscribed units in Amniotics	AQ
27/10/23	Amniotics announces outcome in rights issue	AQ
11/10/23	The subscription period in Amniotics’ rights issue commences today	AQ
10/10/23	Amniotics publishes prospectus in connection with the rights issue of approximately SEK 25 million	AQ
26/09/23	Amniotics granted Singapore patent for its amniotic fluid collection technology	AQ
13/09/23	Final Clinical Study Report received for PulmoStem Phase Ib clinical trial	AQ
06/09/23	Amniotics procures top guarantee commitments and enters into additional subscription undertakings for a fully secured rights issue	AQ
31/08/23	Amniotics AB (publ) Report for the second Quarter 2023	AQ